

INVITATION

BMUC Preceptorship Ghent

Uro-oncology

Thursday 5 & Friday 6 September 2024

Novotel Ghent Centrum Hotel



The background of the entire page is a teal-colored microscopic image showing various cells and structures. There are several large, spherical cells with prominent nuclei and some with long, thin protrusions. The overall texture is grainy and detailed, typical of a scanning electron micrograph.

Dear colleague,

We are pleased to extend an invitation to you for participating in the BMUC Preceptorship in Ghent, taking place on 5 & 6 September 2024. This meeting on genitourinary cancers is organised by BMUC and the University Hospital of Ghent (UZ Gent), in cooperation with the uro-oncology teams of Aalst (OLV & ASZ), with the support of Astellas, J&J, MSD and Pfizer.

The BMUC Preceptorship targets a small group of 30-40 young physicians from various disciplines including medical oncologists, urologists, radiation oncologists and other colleagues involved in uro-oncology. By combining state-of-the-art presentations and clinically relevant cases, it provides a platform for discussion, professional development, exchange of experiences and networking.

We are delighted to welcome an important number of Belgian experts for this meeting. The highly interactive and dynamic nature of the meeting will contribute to a better management of our cancer patients.

We look forward welcoming you in Ghent for an exciting high-level meeting on 5 & 6 September 2024.

Sylvie Rottey
Chair

Preliminary programme

Thursday 5 September 2024

19:00 – 19:30	Registration and welcome
19:30 – 20:15	Artificial Intelligence: The second brain for surgeons? - <i>Niki Rashidian</i>
20:15 – 21:00	Predicting prostate cancer aggressiveness from digital pathology with deep learning - <i>Marija Pijzurica</i>
21:00	Walking dinner

Friday 6 September 2024

08:30 – 08:40	Registration and welcome
08:40 – 10:00	Adjuvant treatment in Bladder and Renal Cancer
	How to communicate the benefits and risks of adjuvant treatment to patients - <i>Daan De Maeseneer</i>
	Cases bladder cancer - <i>Frederiek Dhondt</i>
	Cases renal cancer - <i>Charles Van Praet</i>
10:00 – 10:30	Break
10:30 – 12:30	Redefining the use and duration of systemic treatment
	RCC : Start & Stop Criteria
	Can we stop immunotherapy in RCC (+ case)? - <i>Sylvie Rottey</i>
	Can we postpone start of therapy in RCC (+ case)? - <i>Max Schreuer</i>
	Prostate: To escalate or to de-escalate?
	Statement (+ case) - <i>Peter Schatteman</i>
	Statement (+ case) - <i>Benedikt Engels</i>
12:30 – 13:00	Lunch
13:00 – 15:00	Lnn positive disease in bladder and prostate cancer – how to manage?
	Cases and discussion - <i>Alexander Decruyenaere</i> - <i>Frederiek Dhondt</i> - <i>Valerie Fonteyne</i>
15:00	Closing the meeting

Faculty

Alexander Decruyenaere, Ghent University Hospital, Ghent, Belgium

Daan De Maeseneer, Ghent University Hospital, Ghent, & AZ Sint-Lucas, Bruges, Belgium

Frederiek Dhondt, OLV Hospital Aalst, Aalst, Belgium

Benedikt Engels, OLV Hospital Aalst, Aalst, Belgium

Valérie Fonteyne, Ghent University Hospital, Ghent, Belgium

Marija Pijzurica, Ghent University Hospital, Ghent, Belgium & Stanford University, California, USA

Niki Rashidian, Ghent University Hospital & Training and Research Institute for Surgical AI, Ghent, Belgium

Sylvie Rottey, Ghent University Hospital, Ghent, Belgium

Peter Schatteman, OLV Hospital Aalst, Aalst, Belgium

Max Schreuer, ASZ Aalst, Aalst, Belgium

Charles Van Praet, Ghent University Hospital, Ghent, Belgium

Practical information



Date

Thursday 5 & Friday 6 September 2024



Venue

Novotel Ghent Centrum Hotel, Hoogpoort 52, 9000 Ghent

Tel: +32 9 293 90 02

<https://all.accor.com/hotel/0840/index.en.shtml>



Target audience

Young medical oncologists, urologists, radiation oncologists and those in training for these specialisms.



Registration & information

This meeting is on personal invitation only. Overnight stay is possible.

Interested in participating? Please register via Nathalie.DeBrabander@UGent.be

Mdeon

The Mdeon visa number for this meeting is 24/V2/6815/009547.

Thanks to our Preceptorship sponsors



Johnson&Johnson

